Label-free Assessment of Cardiomyocyte Activity
Understanding and defining the effects of compounds on cardiac function is critically important in drug discovery and toxicity testing. CDI’s iCell Cardiomyocytes and iCell Cardiomyocytes2 provide a relevant and validated system for studying pharmacological effects on human cardiomyocyte activity. Sony Instruments has launched the SI8000 Cell Motion Imaging System for in vitro assessment of cardiomyocyte behavior (Figure 1). As discussed in Hayakawa, et al. (2014), the motion activity of the cardiomyocytes is monitored to determine any drug-induced effects (Figure 2).
Additionally, CDI’s MyCell® products supply disease-specific cardiomyocytes through derivation from disease populations or genetic modification.
Together, these technologies provide a rapid, accurate, and robust label-free measurement of cardiomyocyte activity for use in developing newer, safer, and more effective pharmaceutical agents.
Contact CDI’s Technical Support team to learn more about iCell and MyCell products.
Refer to Sony Biotechnology Inc. to learn more about the SI8000 Cell Motion Imaging System.